The group IVE Ray departed for Tokyo, Japan, on the afternoon of the 15th via Gimpo Airport to attend the '3rd Asia Star ...

EyePoint said on Thursday an independent safety committee found no new concerns in ​two late-stage trials of its experimental eye disease drug ‌Duravyu and recommended the studies continue unchanged.

Since Roche launched its long-acting eye disease medicine Vabysmo in 2022, Bayer and Regeneron have seen the impact on sales of their rival treatment Eylea, with the U.S. biotech taking a bigger hit.

At the conclusion of the inspection on May 8, 2026, the FDA issued a Form 483. The company believes the observations can be addressed quickly and do not raise any substantial issues with the site or ...

Regeneron has leveraged its monoclonal antibody research and development platform to become one of the few biotechs to be a profitable commercial operation and establish a narrow moat. Lead drug Eylea ...

Product Revenues -- $51 million, from major contributors AVT02 (Humira biosimilar) and AVT04 (Stelara biosimilar); ...

Bayer has agreed to acquire Perfuse Therapeutics for up to $2.45 billion, in a deal designed to broaden the buyer’s ophthalmology pipeline with Perfuse’s sole pipeline drug and two clinical phase ...

REYKJAVIK, Iceland, May 06, 2026 (GLOBE NEWSWIRE) -- ...

If approved, the deal’s centrepiece, PER-001, could continue Bayer’s ophthalmology legacy defined by blockbuster retinal ...

DENVER -- A sustained-release VEGF inhibitor implant outperformed standard anti-VEGF therapy for maintaining visual acuity in ...

The German pharmaceutical-and-agricultural group said the acquisition would complement its drug pipeline and leverage its ...

Regeneron is seeing double-digit revenue growth and has more than 50 therapies in its pipeline, making it a good long-term ...